Acquired thrombotic thrombocytopenic purpura is the non-hereditary form of thrombotic thrombocytopenic purpura (TTP), characterized by profound peripheral thrombocytopenia, microangiopathic hemolytic ...
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding acquired TTP reflects its rarity and the complexities of its clinical presentation. Because this condition affects fewer individuals, comprehensive studies have not been feasible, leading to gaps in our understanding of its features and management. This can be frustrating, but ongoing research aims to improve knowledge and treatment options.
To navigate acquired TTP effectively, consider seeking a hematologist with expertise in blood disorders, particularly those familiar with thrombotic microangiopathies. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You may also want to explore opportunities to participate in clinical trials, which can offer access to cutting-edge treatments and contribute to the understanding of this condition. Visit GARD at rarediseases.info.nih.gov for more information.
There are several orphan drugs designated for the treatment of acquired TTP, including Caplacizumab, which is FDA-approved. Additionally, there are multiple drugs in development, such as a fusion protein targeting the von Willebrand factor and other agents like anfibatide and Defibrotide. Currently, there are 6 active clinical trials exploring various treatment options for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=acquired%20thrombotic%20thrombocytopenic%20purpura.
Actionable guidance for navigating care for acquired thrombotic thrombocytopenic purpura
To navigate acquired TTP effectively, consider seeking a hematologist with expertise in blood disorders, particularly those familiar with thrombotic microangiopathies. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You may also want to explore opportunities to participate in clinical trials, which can offer access to cutting-edge treatments and contribute to the understanding of this condition. Visit GARD at rarediseases.info.nih.gov for more information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding acquired TTP reflects its rarity and the complexities of its clinical presentation. Because this condition affects fewer individuals, comprehensive studies have not been feasible, leading to gaps in our understanding of its features and management. This can be frustrating, but ongoing research aims to improve knowledge and treatment options.
To navigate acquired TTP effectively, consider seeking a hematologist with expertise in blood disorders, particularly those familiar with thrombotic microangiopathies. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You may also want to explore opportunities to participate in clinical trials, which can offer access to cutting-edge treatments and contribute to the understanding of this condition. Visit GARD at rarediseases.info.nih.gov for more information.
There are several orphan drugs designated for the treatment of acquired TTP, including Caplacizumab, which is FDA-approved. Additionally, there are multiple drugs in development, such as a fusion protein targeting the von Willebrand factor and other agents like anfibatide and Defibrotide. Currently, there are 6 active clinical trials exploring various treatment options for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=acquired%20thrombotic%20thrombocytopenic%20purpura.
Actionable guidance for navigating care for acquired thrombotic thrombocytopenic purpura
To navigate acquired TTP effectively, consider seeking a hematologist with expertise in blood disorders, particularly those familiar with thrombotic microangiopathies. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You may also want to explore opportunities to participate in clinical trials, which can offer access to cutting-edge treatments and contribute to the understanding of this condition. Visit GARD at rarediseases.info.nih.gov for more information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding acquired TTP reflects its rarity and the complexities of its clinical presentation. Because this condition affects fewer individuals, comprehensive studies have not been feasible, leading to gaps in our understanding of its features and management. This can be frustrating, but ongoing research aims to improve knowledge and treatment options.
To navigate acquired TTP effectively, consider seeking a hematologist with expertise in blood disorders, particularly those familiar with thrombotic microangiopathies. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You may also want to explore opportunities to participate in clinical trials, which can offer access to cutting-edge treatments and contribute to the understanding of this condition. Visit GARD at rarediseases.info.nih.gov for more information.
There are several orphan drugs designated for the treatment of acquired TTP, including Caplacizumab, which is FDA-approved. Additionally, there are multiple drugs in development, such as a fusion protein targeting the von Willebrand factor and other agents like anfibatide and Defibrotide. Currently, there are 6 active clinical trials exploring various treatment options for this condition. For more information on these trials, you can visit ClinicalTrials.gov at https://clinicaltrials.gov/search?cond=acquired%20thrombotic%20thrombocytopenic%20purpura.
Actionable guidance for navigating care for acquired thrombotic thrombocytopenic purpura
To navigate acquired TTP effectively, consider seeking a hematologist with expertise in blood disorders, particularly those familiar with thrombotic microangiopathies. While no specific patient organizations are currently identified, resources like the Genetic and Rare Diseases Information Center (GARD) can provide valuable information and support. You may also want to explore opportunities to participate in clinical trials, which can offer access to cutting-edge treatments and contribute to the understanding of this condition. Visit GARD at rarediseases.info.nih.gov for more information.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 1 company has orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.